Bunanserin API

Name	Bunanserin
Chinese name	布南色林
Cas Number	132810-10-7
Source	Korea
Qualifications	-/-/-/-/-

Bunanserin is a new generation of atypical antipsychotics developed by Japan's Sumitomo Pharmaceutical Co., Ltd. and launched in Japan in April 2008. It belongs to serotonin and dopamine antagonists, and has the effect of blocking dopamine D2 receptors and 5-HT2A receptors. Compared with other antipsychotic drugs currently on the market, its extrapyramidal side effects are less. The affinity of branserin to D2 receptors is 20 and 94 times that of haloperidol and risperidone, respectively, and to adrenaline α1, 2 and β receptors, histamine H1 receptors and cholinergic M1 receptors. The affinity of schizophrenia is low, which effectively improves the positive and negative symptoms of schizophrenia while reducing the risk of adverse reactions. Among the 9 antipsychotic drugs such as aripiprazole, haloperidol, olanzapine, paliperidone, quetiapine, and risperidone, branserin has the lowest risk of weight gain. From 2018 to 2019, the global sales of Bunanserin were 713 million yuan and 771 million yuan respectively, and the sales trend maintained growth.

Hot Tags: bunanserin api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Dapoxetine API, Escitalopram Oxalate API, Tippyridine Hydrochloride API, Perindopril Tert butylamine Salt API, Lercanidipine Hydrochloride API, Ulipristal Acetate API

• Previous: Sildenafil Citrate API
• Next: Etonogestrel API